N~2~-methylalaninamide(SALTDATA: FREE)
![]() |
- $65 - $1385
- Product name: N~2~-methylalaninamide(SALTDATA: FREE)
- CAS: 32012-16-1
- MF: C4H10N2O
- MW: 102.14
- EINECS:
- MDL Number:MFCD11176109
- Synonyms:N~2~-methylalaninamide(SALTDATA: FREE);N~2~-methylalaninamide;Propanamide, 2-(methylamino)-;N~2~-methylalaninamide(SALTDATA: FREE) USP/EP/BP
4 prices
Selected condition:
Brand
- ChemBridge Corporation
- Crysdot
- Sigma-Aldrich
- TRC
Package
- 50mg
- 1g
- 5g
- 10g
- ManufacturerChemBridge Corporation
- Product numberBB-4031071
- Product descriptionN~2~-methylalaninamide 95%
- Packaging10g
- Price$1385
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD21008672
- Product description2-(Methylamino)propanamide 95+%
- Packaging5g
- Price$750
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product numberCBR00065
- Product descriptionN2-Methylalaninamide Aldrich
- Packaging1g
- Price$482
- Updated2024-03-01
- Buy
- ManufacturerTRC
- Product numberM103653
- Product descriptionN-2-methylalaninamide
- Packaging50mg
- Price$65
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
ChemBridge Corporation | BB-4031071 | N~2~-methylalaninamide 95% | 10g | $1385 | 2021-12-16 | Buy |
Crysdot | CD21008672 | 2-(Methylamino)propanamide 95+% | 5g | $750 | 2021-12-16 | Buy |
Sigma-Aldrich | CBR00065 | N2-Methylalaninamide Aldrich | 1g | $482 | 2024-03-01 | Buy |
TRC | M103653 | N-2-methylalaninamide | 50mg | $65 | 2021-12-16 | Buy |
Properties
Melting point :124 °C
Boiling point :220.0±23.0 °C(Predicted)
Density :0.976±0.06 g/cm3(Predicted)
pka :16.14±0.50(Predicted)
form :solid
Boiling point :220.0±23.0 °C(Predicted)
Density :0.976±0.06 g/cm3(Predicted)
pka :16.14±0.50(Predicted)
form :solid
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||
Precautionary statements: |
|